ARS Pharmaceuticals, Inc. (SBTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about ARS Pharmaceuticals, Inc. (SBTX)
Company Performance

Current Price

as of Oct 16, 2024

$16.52

P/E Ratio

N/A

Market Cap

$1.6B

Description

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Metrics

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerSBTX
  • Price$16.52+8.47%

Trading Information

  • Market Cap$1.60B
  • Float50.55%
  • Average Daily Volume (1m)964,283
  • Average Daily Volume (3m)1,113,592
  • EPS-$0.47

Company

  • Revenue$0.50M
  • Rev Growth (1yr)4,900.00%
  • Net Income-$12.52M
  • Gross Margin96.40%
  • EBITDA Margin-3,064.40%
  • EBITDA-$15.32M
  • EV$605.42M
  • EV/Revenue1,210.84
  • P/EN/A
  • P/S3,199.19
  • P/B7.44
Documents
SEC Filings
8-K (2024-10-15)
8-K (2024-09-23)
8-K (2024-08-12)
8-K (2024-08-06)
8-K (2024-06-28)
8-K (2024-06-21)
8-K (2024-05-10)
8-K (2024-05-09)
8-K (2024-03-21)
8-K (2024-03-07)
8-K (2023-11-09)
8-K (2023-09-25)
8-K (2023-09-20)
8-K (2023-08-10)
8-K (2023-06-28)
8-K (2023-05-16)
8-K (2023-05-15)
8-K (2023-05-09)
8-K (2023-03-23)
8-K (2023-03-13)
8-K (2023-02-22)
8-K (2023-02-14)
10-Q (2024-08-06)
10-Q (2024-05-09)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-05-15)
10-K (2024-03-21)
10-K (2023-03-23)
Factset Street Account
ARS Pharmaceuticals reports Q3 EPS ($0.16) vs FactSet ($0.18) [3 est, ($0.20)-(0.14)] ($3.43, 0.00) (2023-11-09T21:25:56Z)
ARS Pharmaceuticals announces publication of full results from registration study of neffy ($3.84, 0.00) (2023-10-03T13:09:03Z)
ARS Pharmaceuticals announces presentation of data supporting neffy (epinephrine nasal spray) for the treatment of Allergic Reactions (Type I) including Anaphylaxis ($3.45, -0.14) (2023-11-09T16:05:00Z)